Here you can find the latest TOPADUR news & events.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.
The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.
Do you need more information or references? Media contact